Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $0.42 USD
Change Today +0.0299 / 7.67%
Volume 27.8K
BGMD On Other Exchanges
As of 5:20 PM 10/8/15 All times are local (Market data is delayed by at least 15 minutes).

bg medicine inc (BGMD) Snapshot

Previous Close
Day High
Day Low
52 Week High
01/30/15 - $4.88
52 Week Low
09/16/15 - $0.34
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for BG MEDICINE INC (BGMD)

bg medicine inc (BGMD) Related Businessweek News

No Related Businessweek News Found

bg medicine inc (BGMD) Details

BG Medicine, Inc., a commercial stage company, engages in developing and commercializing diagnostic products used to guide the patients suffering from heart failure and related disorders. The company offers BGM Galectin-3 Test, an in vitro diagnostic device that measures galectin-3 in serum or plasma by enzyme linked immunosorbent assay on a microtiter plate platform; and CardioSCORE Test, a multi-analyte biomarker-based blood test used for the assessment of near-term risk of atherothrombotic cardiovascular events, such as heart attack and ischemic stroke. It has license, development, and commercialization agreements with Abbott Laboratories, bioMérieux SA, Siemens Healthcare Diagnostics Inc., and Alere Inc. for the automated instrument versions of galectin-3 test; and a strategic collaboration with Abbott Laboratories to develop and commercialize galectin-3 assay kits, and related control kits and calibrators. The company was formerly known as Beyond Genomics, Inc. and changed its name to BG Medicine, Inc. in October 2004. BG Medicine, Inc. was founded in 2000 and is headquartered in Waltham, Massachusetts.

7 Employees
Last Reported Date: 03/31/15
Founded in 2000

bg medicine inc (BGMD) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $400.0K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $290.0K
Chief Scientific Officer and Senior Vice Pres...
Total Annual Compensation: $275.0K
Compensation as of Fiscal Year 2014.

bg medicine inc (BGMD) Key Developments

Timothy Harris Resigns to Board of Directors and Audit Committee of BG Medicine, Inc

On September 21, 2015, Timothy Harris, Ph.D., notified BG Medicine, Inc. that he was resigning from the Company's Board of Directors, effective as of September 22, 2015. In connection with his departure from the Board, Dr. Harris also departs from the Board's Audit Committee, which will continue to be comprised of Harrison M. Bains (Chair) and Stelios Papadopoulos, Ph.D.

BG Medicine Receives Delisting Notice From NASDAQ

On September 14, 2015, BG Medicine, Inc. received a letter indicating that the NASDAQ Listing Qualifications Hearings Panel has determined to delist the shares of the Company’s common stock from The NASDAQ Stock Market LLC (NASDAQ), and will suspend trading in the Company’s common stock on NASDAQ effective at the open of business on Wednesday, September 16, 2015. The suspension is due to the Company’s continuing non-compliance with the stockholders’ equity requirement set forth in NASDAQ Listing Rule 5550(b) as of September 10, 2015, as required by the Panel’s decision in this matter. NASDAQ further indicated that it would complete the delisting action by filing a Form 25 Notification of Delisting with the Securities and Exchange Commission after applicable appeal periods have lapsed. The Company expects that its common stock will be eligible for quotation on the OTC Markets’ OTCQB market tier, an electronic quotation service operated by OTC Markets Group Inc. for eligible securities traded over-the-counter, effective at the open of business on September 16, 2015. The Company’s common stock will continue to trade under its current trading symbol “BGMD.”

BG Medicine, Inc.(NasdaqCM:BGMD) dropped from NASDAQ Composite Index

BG Medicine, Inc. will be removed from Nasdaq Composite Index.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BGMD:US $0.42 USD +0.0299

BGMD Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Alere Inc $47.29 USD -0.57
BioMerieux €94.43 EUR +0.43
Koninklijke Philips NV €22.20 EUR +0.125
Laboratory Corp of America Holdings $111.71 USD +0.04
Quest Diagnostics Inc $63.00 USD +0.32
View Industry Companies

Industry Analysis


Industry Average

Valuation BGMD Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 1.5x
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales 1.1x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BG MEDICINE INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at